Jia, J., Niedzwiecki, D., Arrowood, C., Garett-Mead, N., Nagy, R., Lanman, R. B., … Strickler, J. H. (2020). A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Jia, Jingquan, Donna Niedzwiecki, Christy Arrowood, Nancy Garett-Mead, Rebecca Nagy, Richard B. Lanman, John Wright, Andrew B. Nixon, and John H. Strickler. “A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Jia J, Niedzwiecki D, Arrowood C, Garett-Mead N, Nagy R, Lanman RB, et al. A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Jia, Jingquan, et al. “A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 4, 2020.

Jia J, Niedzwiecki D, Arrowood C, Garett-Mead N, Nagy R, Lanman RB, Wright J, Nixon AB, Strickler JH. A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA. JOURNAL OF CLINICAL ONCOLOGY. 2020.